The lowest doses of hIL-18 given to lymphoma patients resulted in IL-18 plasma levels of > 10 ng/mL and biomarker studies have shown in vivo activation rather than suppression of NK cells during IL-18-based immunotherapy (20, 87). Here, IL18 is linked to lymphoma.